Posters

Taryn Dailey-Govoni, Jared Beaumont, Theresa Cassidy Inflexxion, Inc., Waltham, MA, USA Presented at PAINWeek 2017 Read our poster for “Profiling non-medical use of tapentadol products among recreational drug abusers” here Abstract Purpose Prescription opioid misuse and abuse is a public health epidemic in the United States (ONDCP 2015) and a growing source of morbidity, mortality, […]

Jared Beaumont, M.P.H.1, Theresa Cassidy, M.P.H.1, Taryn Dailey Govoni, M.P.H.1 Presented at International Conference on Opioids 2017 See our poster for “Abuse and route of administration prevalence for tapentadol products within the NAVIPPRO® ASI-MV® surveillance system” here Abstract Post-market surveillance data indicate low abuse levels of tapentadol products, but research regarding the route of administration […]

Kimberlee J. Trudeau, Joanna Burtner, Kruti Joshi, Albert Villapiano, Megan Jones, & Stephen F. Butler Presented at ARM 2016 See our poster for “A Cross-Sectional Analysis of Economic, Medical, and Legal Outcomes of Adults in Substance Abuse Treatment centers with Possible or Probable Schizophrenia” here Research Objective:  In the fragmented US healthcare system, patients seeking substance abuse […]

Earlier this year, Inflexxion and KemPharm Pharmaceuticals presented a poster at the International Conference on Opioids based on a recent study of non-medical use of prescription opioids.  According to SAMSHA, Non-medical use of prescription opioids continues to increase.  However, little is known about the potential impact commonly prescribed opioids, such as hydrocodone combination products (HCPs), have […]

Theresa A. Cassidy, MPH, Natasha K. Oyedele, MPH, Jared Beaumont, MPH, Stephen F. Butler, PhD Presented at PAINWeek 2015 See our poster for “Patterns of abuse of hydrocodone combination products: Results from an Internet survey of recreational drug users” here Summary: Researchers conducted this study to examine the progression of hydrocodone combination products (HCP) abuse, routes of administration, and […]

Theresa A. Cassidy, Jared Beaumont, Veronica Urdaneta, Simon H. Budman, Stephen F. Butler Presented at PAINWeek 2014 See our poster for “The changing abuse ecology: implications for evaluating the abuse pattern of extended-release oxymorphone and abuse-deterrent opioid formulations” here Abstract Purpose FDA Guidelines released in January 2013 on evaluating abuse-deterrent formulations (ADFs) recommend direct comparison […]

Stephen F. Butler, PhD, Theresa A. Cassidy, MPH, Taryn Dailey,  BA1, & Paul M. Coplan, ScD2, Presented at CPDD 2014 See our poster for “Comparing abuse of extended-release versus immediate-release opioid analgesics adjusted for number of prescriptions and morphine-equivalent dose” here Abstract Aims: It has been suggested that abuse risk of extended-release (ER) opioids is […]

Theresa A. Cassidy, MPH, Simon H. Budman, PhD, Stephen F. Butler, PhD Presented at CPDD 2014 See our poster for “Evaluation of an ADF product’s route of administration profile” here Abstract Aims: Assessing the impact on abuse patterns of the introduction of abuse deterrent opioid formulations (ADFs) has focused, in part, on comparisons of the […]

Theresa A. Cassidy, MPH, Emily C. McNaughton, MPH , Kimberly Lobo, MPH , Simon H. Budman, PhD, Stephen F. Butler, PhD Presented at American Society of Addiction Medicine (ASAM), Chicago, IL, April 25-27th, 2013  See our poster for “Abuse of Reformulated OPANA® ER: early findings from NAVIPPRO® data” here Abstract Summary: Reformulated extended release (ER) oxymorphone (OPANA […]

Theresa A. Cassidy, MPH, Emily C. McNaughton, MPH , Stephen F. Butler, PhD, Simon H. Budman, PhD Presented at PAINWeek 2012 See our poster for “Change in prescription opioid abuse after introduction of an abuse deterrent formulation” here Abstract OBJECTIVE: The reformulation of oxycodone hydrochloride controlled-release (CR) tablets in August 2010 created a natural experiment […]

S.F. Butler, H. Chilcoat, T.A. Cassidy, R.A. Black, C. Landau, S.H. Budman, P. Coplan Presented at IASP Milan 2012 See our poster for “Differences in rates of abuse and routes of administration for original and reformulated extended-release oxycodone among individuals assessed for substance abuse” here Abstract Oxycodone hydrochloride controlled-release, also known as extended-release oxycodone (ER oxycodone), […]

Ryan Black, Paul Coplan, Theresa A. Cassidy, Howard Chilcoat, Simon H. Budman, Craig Landau, Stephen F. Butler Presented at APS Public Health 2012 See our poster for “Effects of reformulated OxyContin® among patients assessed for substance abuse treatment in the NAVIPPRO sentinel surveillance network” here Abstract Reformulated OxyContin® (oxycodone HCl controlled-release) Tablets (ORF) have physiochemical […]